Mirum Pharmaceuticals (MIRM) Stock Price, Quote, News & History

Comments

Mirum Pharmaceuticals Inc (MIRM) Stock Price, Quote, News & History

MIRMNASDAQ

Trade with Public

$88.51

-2.21-2.44%

At close: Mar 20, 5:00 PM EST

$88.51

N/A

After Hours: Mar 20, 4:00 PM EST

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$90.73

Close

$88.51

Volume / Avg.

2.23M / 833.89K

Day Range

$86.90 - $91.70

52 Wk Range

36.88 - 109.28

Market Cap

$5.30B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

12.73%

Days to Cover

9.75

Recent Mirum Pharmaceuticals Inc News

FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol

Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.

Vandana Singh

Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

55.83M

Investing Cash Flow (TTM)

-23.95M

Financing Cash Flow (TTM)

40.14M

Free Cash Flow (TTM)

54.87M

Capital Expenditure (TTM)

-954.00K

Net Change in Cash (TTM)

72.02M

Analyst Trends and Forecast

2

Nov 25

5

Dec 25

3

Jan

5

Feb

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.28B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

8.73

PB Ratio (TTM)

17.39

Earnings Yield % (TTM)

-0.52%

Earnings Yield % (FWD)

-1.28%

EV / EBITDA (TTM)

314.37

Price / EBITDA (TTM)

264.62

Price / Free Cash Flow (TTM)

82.97

Book Value / Share

$5.22

Company Debt

Total Debt

$309.80M

LT Debt

$309.80M

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-

Total Cash

$296.68M

Debt to Equity

1.02

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

-

Key Statistics

Open

$90.73

Close

$88.51

Volume / Avg.

2.23M / 833.89K

Day Range

$86.90 - $91.70

52 Wk Range

36.88 - 109.28

Market Cap

$5.30B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

12.73%

Days to Cover

9.75

About

Sector

Health Care

Industry

Biotechnology

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestat...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Mirum Pharmaceuticals (MIRM) stock?

A

You can purchase shares of Mirum Pharmaceuticals (NASDAQ:MIRM) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Mirum Pharmaceuticals (MIRM) competitors?

A

Other companies in Mirum Pharmaceuticals’s space includes: Immunovant Inc (NASDAQ:IMVT), Cogent Biosciences Inc (NASDAQ:COGT), Celcuity Inc (NASDAQ:CELC), Centessa Pharmaceuticals PLC (NASDAQ:CNTA) and Xenon Pharmaceuticals Inc (NASDAQ:XENE).

Q

What is the forecast, or price target, for Mirum Pharmaceuticals (MIRM) stock?

A

Mirum Pharmaceuticals has a consensus price target of $95.63.

Q

What is the current price for Mirum Pharmaceuticals (MIRM)?

A

The stock price for Mirum Pharmaceuticals (NASDAQ: MIRM) is $88.51 last updated March 20, 2026 at 4:00 PM EDT.

Q

Does Mirum Pharmaceuticals (MIRM) pay a dividend?

A

There are no upcoming dividends for Mirum Pharmaceuticals.

Q

When is Mirum Pharmaceuticals (NASDAQ:MIRM) reporting earnings?

A

Mirum Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Mirum Pharmaceuticals (MIRM) going to split?

A

There is no upcoming split for Mirum Pharmaceuticals.

Q

What sector and industry does Mirum Pharmaceuticals (MIRM) operate in?

A

Mirum Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Cogent Biosciences Inc

Centessa Pharmaceuticals PLC

NASDAQ:CNTA

$27.06

%

Xenon Pharmaceuticals Inc

Protagonist Therapeutics Inc

NASDAQ:PTGX

$100.01

1.15%

Key Statistics

Open

$90.73

Close

$88.51

Volume / Avg.

2.23M / 833.89K

Day Range

$86.90 - $91.70

52 Wk Range

36.88 - 109.28

Market Cap

$5.30B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

12.73%

Days to Cover

9.75

Recent Mirum Pharmaceuticals Inc News

FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol

Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.

Vandana Singh

Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

55.83M

Investing Cash Flow (TTM)

-23.95M

Financing Cash Flow (TTM)

40.14M

Free Cash Flow (TTM)

54.87M

Capital Expenditure (TTM)

-954.00K

Net Change in Cash (TTM)

72.02M

Analyst Trends and Forecast

2

Nov 25

5

Dec 25

3

Jan

5

Feb

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.28B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

8.73

PB Ratio (TTM)

17.39

Earnings Yield % (TTM)

-0.52%

Earnings Yield % (FWD)

-1.28%

EV / EBITDA (TTM)

314.37

Price / EBITDA (TTM)

264.62

Price / Free Cash Flow (TTM)

82.97

Book Value / Share

$5.22

Company Debt

Total Debt

$309.80M

LT Debt

$309.80M

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-

Total Cash

$296.68M

Debt to Equity

1.02

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

-

Key Statistics

Open

$90.73

Close

$88.51

Volume / Avg.

2.23M / 833.89K

Day Range

$86.90 - $91.70

52 Wk Range

36.88 - 109.28

Market Cap

$5.30B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

12.73%

Days to Cover

9.75

About

Sector

Health Care

Industry

Biotechnology

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestat...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry